Key Points
- CFO Kory James Wentworth sold 8,910 shares on November 21 at an average price of $9.98 for $88,921.80, reducing his stake by 7.49% to 110,026 shares (valued at about $1.10M), according to an SEC filing.
- Entrada missed expectations in its most recent quarter, reporting EPS of ($1.06) versus a ($1.04) consensus and revenue of $1.61M compared to $8.62M expected, with negative return on equity and net margin.
- The stock trades near $9.89 with a market cap of $378M and a 1‑year range of $4.93–$21.79; analysts show a mixed outlook but an average rating of "Moderate Buy" and an average price target of $20.67, while institutional ownership is about 86.4%.
Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) CFO Kory James Wentworth sold 8,910 shares of the business's stock in a transaction that occurred on Friday, November 21st. The shares were sold at an average price of $9.98, for a total transaction of $88,921.80. Following the completion of the transaction, the chief financial officer owned 110,026 shares of the company's stock, valued at $1,098,059.48. The trade was a 7.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.
Entrada Therapeutics Trading Down 2.2%
NASDAQ TRDA opened at $9.89 on Tuesday. The firm's 50 day simple moving average is $6.72 and its 200 day simple moving average is $6.68. The firm has a market capitalization of $378.00 million, a price-to-earnings ratio of -3.97 and a beta of -0.09. Entrada Therapeutics, Inc. has a 1 year low of $4.93 and a 1 year high of $21.79.
Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last released its earnings results on Thursday, November 6th. The company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($1.04) by ($0.02). Entrada Therapeutics had a negative return on equity of 26.42% and a negative net margin of 168.16%.The business had revenue of $1.61 million for the quarter, compared to the consensus estimate of $8.62 million. On average, equities research analysts forecast that Entrada Therapeutics, Inc. will post 1.12 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of research analysts have issued reports on TRDA shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Entrada Therapeutics in a research report on Wednesday, October 8th. Zacks Research raised shares of Entrada Therapeutics to a "hold" rating in a report on Friday, August 8th. Wall Street Zen cut shares of Entrada Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, August 9th. Finally, Roth Capital set a $13.00 target price on shares of Entrada Therapeutics in a research report on Thursday, November 6th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Entrada Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $20.67.
Read Our Latest Research Report on TRDA
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the company. State of Wyoming raised its holdings in Entrada Therapeutics by 130.9% in the 2nd quarter. State of Wyoming now owns 7,575 shares of the company's stock valued at $51,000 after buying an additional 4,295 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of Entrada Therapeutics by 72.7% during the third quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company's stock worth $51,000 after purchasing an additional 3,707 shares during the period. Occudo Quantitative Strategies LP acquired a new position in shares of Entrada Therapeutics during the second quarter worth $68,000. IHT Wealth Management LLC bought a new stake in shares of Entrada Therapeutics in the second quarter worth $72,000. Finally, Trexquant Investment LP acquired a new stake in Entrada Therapeutics in the first quarter valued at $101,000. Institutional investors and hedge funds own 86.39% of the company's stock.
About Entrada Therapeutics
(
Get Free Report)
Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
